- Home
- MGTX vs IMTX Comparison
MGTX vs IMTX Comparison
Compare MGTX & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- IMTX
- Stock Information
- Founded
- MGTX 2015
- IMTX N/A
- Country
- MGTX United States
- IMTX Germany
- Employees
- MGTX N/A
- IMTX N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGTX Health Care
- IMTX Health Care
- Exchange
- MGTX Nasdaq
- IMTX Nasdaq
- Market Cap
- MGTX 670.2M
- IMTX 653.9M
- IPO Year
- MGTX N/A
- IMTX N/A
- Fundamental
- Price
- MGTX $7.29
- IMTX $5.09
- Analyst Decision
- MGTX Strong Buy
- IMTX Strong Buy
- Analyst Count
- MGTX 2
- IMTX 4
- Target Price
- MGTX $24.00
- IMTX $14.67
- AVG Volume (30 Days)
- MGTX 321.7K
- IMTX 737.1K
- Earning Date
- MGTX 08-14-2025
- IMTX 08-13-2025
- Dividend Yield
- MGTX N/A
- IMTX N/A
- EPS Growth
- MGTX N/A
- IMTX N/A
- EPS
- MGTX N/A
- IMTX N/A
- Revenue
- MGTX $37,917,000.00
- IMTX $152,823,253.00
- Revenue This Year
- MGTX $145.67
- IMTX N/A
- Revenue Next Year
- MGTX $167.61
- IMTX N/A
- P/E Ratio
- MGTX N/A
- IMTX N/A
- Revenue Growth
- MGTX 366.84
- IMTX 83.61
- 52 Week Low
- MGTX $3.85
- IMTX $3.30
- 52 Week High
- MGTX $8.98
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- MGTX 41.87
- IMTX 33.44
- Support Level
- MGTX $7.34
- IMTX $5.16
- Resistance Level
- MGTX $7.75
- IMTX $5.56
- Average True Range (ATR)
- MGTX 0.40
- IMTX 0.37
- MACD
- MGTX -0.07
- IMTX -0.11
- Stochastic Oscillator
- MGTX 7.78
- IMTX 2.76
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.